# Null Hypothesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/null-hypothesis

- Industry: Internet
- Headquarters: Shanghai, China
- Website: www.nullht.com/
- Total disclosed funding: $14M
- Latest round: Series A (Nov 4, 2025)
- Investors on record: 3

## About

Established in 2019 and based in Hangzhou, China, Null Hypothesis is a medical SaaS platform that provides SaaS products for the intelligent output of medical content. In November 2025, Null Hypothesis raised CNY 100 million in series A funding from new investors Lotus Lake Capital, Growth Investment, and Shanghai Zheyu Technology. Returning investor Oriza Holdings and other unspecified investors also participated in the round.

The company independently developed the KnowS series of virtual medical assistant products, including Express and Competition. It serves pharmaceutical and medical device companies, tertiary hospitals, doctors, and other medical industries. The platform allows access to academic resources, provides scientific research solutions for pharmaceutical companies and doctors, and helps pharmaceutical and medical device companies build a commercialization system.

The company generates revenue by providing medically intelligent KnowS series products.

The company will use the November 2025 funding to advance its AI tools for better communication between drug makers and physicians.

## Funding rounds

- Series A, Nov 4, 2025, $14M — Oriza Holdings, Lotus Lake Capital, Shanghai Zheyu Investment

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Shanghai Zheyu Investment — Series A